The Carrier Screening Market is estimated to be valued at US$ 1.9 billion in 2021 and is expected to exhibit a CAGR of 13.8% over the forecast period 2021-2031, as highlighted in a new report published by Coherent Market Insights.
Carrier screening is a form of genetic testing that is performed to determine if an individual carries a gene mutation for certain inherited disorders. It is primarily used to identify carriers of genetic disorders such as cystic fibrosis, sickle cell disease, and thalassemia, among others. The rising prevalence of genetic disorders and the increasing awareness about the importance of genetic testing are expected to drive the growth of the carrier screening market. Moreover, advancements in technology and the availability of novel screening tests are further contributing to market growth.
The carrier screening market is driven by two main factors. The first driver is the increasing incidence of genetic disorders, which is leading to a higher demand for carrier screening tests. With a growing number of individuals being affected by genetic disorders, there is a need for early detection and prevention strategies, which has boosted the adoption of carrier screening tests.
The second driver is the growing awareness about genetic testing among individuals and healthcare professionals. The increasing knowledge about the benefits of carrier screening in identifying the risk of passing on genetic disorders to offspring is encouraging more individuals to undergo these tests. Additionally, healthcare providers are promoting increased genetic testing to facilitate better patient care and management of genetic disorders.
Overall, the carrier screening market is expected to witness high growth due to the increasing incidence of genetic disorders and the growing awareness about genetic testing.
The Carrier Screening market is segmented by test type, technology, application, end-user, and region. Among these segments, the test type segment dominates the market due to the increasing prevalence of genetic diseases and the rising demand for early detection and prevention. Carrier Screening tests are used to identify carriers of genetic disorders, allowing individuals to make informed decisions regarding family planning. Moreover, technological advancements in genetic testing have improved the accuracy and efficiency of Carrier Screening tests, further driving the dominance of this segment.
Political: The political landscape plays a crucial role in the Carrier Screening market. Government regulations and policies regarding genetic testing, ethical considerations, and privacy concerns can impact market growth.
Economic: Economic factors like healthcare expenditure, insurance coverage, and disposable income influence the adoption of Carrier Screening tests. The affordability and accessibility of these tests can affect market demand.
Social: Growing awareness about genetic disorders, changing societal attitudes towards family planning, and increasing emphasis on personalized medicine are social factors shaping the Carrier Screening market.
Technological: Technological advancements such as next-generation sequencing, non-invasive prenatal testing, and advanced data analytics have revolutionized Carrier Screening tests, leading to increased accuracy and faster results.
The Global Carrier Screening Market Demand is expected to witness high growth, exhibiting a CAGR of 13.8% over the forecast period due to increasing awareness about genetic disorders and the rising demand for early detection and prevention. The market size is projected to reach $1.9 billion in 2021.
Regionally, North America is the fastest-growing and dominating region in the Carrier Screening market. The presence of key players, advanced healthcare infrastructure, and favorable government initiatives supporting genetic testing contribute to the region’s dominance.
Key players operating in the Carrier Screening market include Invitae Corporation, Thermo Fisher Scientific, Quest Diagnostics, Sema4, Myriad Genetics, Inc., Illumina, Inc., Fulgent Genetics, Gene by Gene, CENTOGENE N.V., QIAGEN, Eurofins Scientific, Luminex Corporation, Medgenome, and others. These key players focus on strategic collaborations, mergers and acquisitions, and technological advancements to gain a competitive edge in the market.